MTOR and prostate carcinoma: In prostate cancer, PIK3R1 is rarely mutated (0.4–1.6% of cases) yet deep deletions occur in 1–6% of patients (Tables S1–S3), which could potentially promote PI3K-AKT-mTOR signaling.